Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials


Journal article


Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, Carolin Bürkle, Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann
Blood, vol. 127(18), 2016 Apr 5, pp. 2189-2192

Cite

APA
Böll, B., Goergen, H., Behringer, K., Bröckelmann, P. J., Hitz, F., Kerkhoff, A., … Borchmann, P. (2016). Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood, 127(18), 2189–2192.

Chicago/Turabian
Böll, Boris, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, et al. “Bleomycin in Older Early-Stage Favorable Hodgkin Lymphoma Patients: Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials.” Blood 127, no. 18 (April 5, 2016): 2189–2192.

MLA
Böll, Boris, et al. “Bleomycin in Older Early-Stage Favorable Hodgkin Lymphoma Patients: Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials.” Blood, vol. 127, no. 18, Apr. 2016, pp. 2189–92.